The 24-page SEC PDF against Holmes is online at SEC here. Less-noted is the 23-age SEC complaint against Balwani - which describes him as Holmes' one-time boyfriend; here.
Coverage today, including open access coverage, is widespread. See e.g. WSJ, Bloomberg, Forbes. NYT article, NYT OpEd. Political view at Vox. Update; May 2018 coverage of the boyfriend, WSJ, here.
The decline of Theranos is usually traced to an October 2015 expose' by WSJ's John Carreyou (for the story on the story, here). And in April 2016, David Boies was still telling NYT that he and the board have complete faith in the CEO. But by April or May 2016, Medicare data would have been published showing they had only $15,000 in Medicare billings in 2014, although they confirmed to investors that in 2014 they had $100M in revenue. See below.
I kept an online running inventory of web articles about Theranos from December 2014 to December 2016, totaling about 500 links. Here.
The case has two aspects: (1) overstatements of the success of the Edison point-of-care platform, and (2) overstatements about actual revenue. This second story is much newer and is my focus here.
Using SEC filings, WSJ shows charts of $600M investor cash raised by 2014. WSJ asserts that Theranos stated revenue of $108M in 2014 versus $100,000 actual:
|SEC filing 3/14/2018|
Discrepancies between lab revenue claimed versus actual would have materialized annually from Medicare public access records. I've put Theranos Medicare payments in the cloud for CY2014 and CY2015, but these are just pulls from the open access CMS dataset.
- From this data, for Theranos billing under NPI 158-854-6401, CY2014 payments from Medicare Part B were $15,311.
- Blood draw was billed for 574 unique Medicare patients.
- Theranos billed the US Medicare program for less than 50 cases of most lab tests it billed. (Generally, it charged CMS the CMS fee schedule amount).
- CY2015 payments, from the same data for same NPI, were $128,804.
- Very few beneficiaries had more than 1 lab test per type of test. E.g. "1" of test X and "1" of test Y per year.
If Theranos stated to investors in early 2015 its 2014 lab revenue was $100M, what did they expect the reaction to be in May 2016 when data was public that its Medicare 2014 lab revenue was $15,000?
This financial issue would have come out and been the same story, even if the Edison lab machine had worked perfectly. Even if John Carreyou had never heard of them. It's remarkable. It's not just a "misleading story" like convincing yourself the Edison is better that it is, or holding a delusional belief it is getting better faster than it is. The financial statements can't be classed as wishful or misguided; they were like jumping off a building without a parachute.
|CY2015 Part B to Theranos. Click to enlarge.|
BuzzFeed has an interesting approach, mining public "Glassdoor Reviews" comments by employees about life at Theranos, here. For Buzzfeed's take on 7 biggest lies, here.
SEC case; a key financials page: click to enlarge.
|SEC financials. Click to enlarge.|
Regarding tests per patient. For 85025, CBC, Theranos did about 1.05 tests per patient. Quest did 1.6, with some Quest centers doing >2 per patient (same database; data not shown).
On a personal note, as an MBA working with larger and smaller startups, I'm still amazed they could raise >$500M while the CEO owned half of the company but controlled 99% of the voting stock, and the board members were 85 year olds who knew nothing about healthcare or technology, rather than voting investors. It's an overused word, but it is - amazing.